Malan IA. Atrial Fibrillation and Hemodialysis – Should we Anticoagulate These Patients? Ischemic Versus Hemorrhagic Risk. International Journal of Cardiovascular Sciences 2022;35(6):757-9.
Malan, Iara Atié. Atrial Fibrillation and Hemodialysis – Should we Anticoagulate These Patients? Ischemic Versus Hemorrhagic Risk. International Journal of Cardiovascular Sciences, v. 35, n. 6, p. 757-759, Nov. 2022.
Malan, I. A. (2022). Atrial Fibrillation and Hemodialysis – Should we Anticoagulate These Patients? Ischemic Versus Hemorrhagic Risk. International Journal of Cardiovascular Sciences, 35(6), 757-759.
Malan, Iara Atié. Atrial Fibrillation and Hemodialysis – Should we Anticoagulate These Patients? Ischemic Versus Hemorrhagic Risk. International Journal of Cardiovascular Sciences [online]. 2022, vol. 35, n. 6, [cited 2026-10-14], pp. 757-759. Available from: <https://journals.cardiol.br/en/article/atrial-fibrillation-and-hemodialysis-should-we-anticoagulate-these-patients-ischemic-versus-hemorrhagic-risk/>. ISSN 2359-4802